3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
15
Paraganglioma
4
Meningioma
4
Carcinoma, Neuroendocrine
4
Pheochromocytoma
3
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Somatostatinoma
1
Serotonin Syndrome
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Disease Progression
1
Carcinoma, Merkel Cell
1
Carcinoid Heart Disease
1
Breast Neoplasms
1
Advanced Lung Neuroendocrine Tumor
1
Adenoma, Islet Cell
1
Interventions
telotristat ethyl
3
telotristat
1
pasireotide
1
lutetium Lu 177 dotatate
1
alpha-methyltryptophan
1
Random Allocation
1
Panitumumab
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Serotonin Syndrome
×
lutetium Lu 177 dotatate
×
Clear all
NCT04039516
2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2
Unknown
20 enrolled